Contemporary management of neuropathic pain for the primary care physician

Mayo Clinic Proceedings

Volumn 79, Issue 12, 2004, Pages 1533-1545

  Chen, Hsiupei ^a,f   Lamer, Tim J ^b   Rho, Richard H ^c   Marshall, Kenneth A ^b,d   Sitzman, B Todd ^b,e   Ghazi, Salim M ^b   Brewer, Randall P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c Mayo Clinic   (United States)

^d Oconee Memorial Hospital   (United States)

^e Wesley Medical Center   (United States)

^f Critical Health Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BACLOFEN; CARBAMAZEPINE; CITALOPRAM; CLONIDINE; DEXTROPROPOXYPHENE; DULOXETINE; FENTANYL; GABAPENTIN; LAMOTRIGINE; LIDOCAINE; METHADONE; MEXILETINE; MORPHINE; NORTRIPTYLINE; OPIATE; OXYCODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; VENLAFAXINE;

ACUTE TOXICITY; AGRANULOCYTOSIS; ANOREXIA; ANXIETY DISORDER; APLASTIC ANEMIA; APPETITE DISORDER; ATAXIA; BODY WEIGHT DISORDER; BONE METASTASIS; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COMPLEX REGIONAL PAIN SYNDROME; CONFUSION; CONSTIPATION; CYTOMEGALIC INCLUSION BODY DISEASE; DEPRESSION; DEVELOPMENTAL COORDINATION DISORDER; DIABETIC NEUROPATHY; DIPLOPIA; DIZZINESS; DRUG SAFETY; DYSPHORIA; DYSTONIA; ERYTHEMA; FATIGUE; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALGESIA; HYPERTENSION; HYPONATREMIA; INSOMNIA; LEUKOPENIA; LOW BACK PAIN; NAUSEA; NERVE COMPRESSION; NERVE CONDUCTION; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PARANEOPLASTIC SYNDROME; PERIPHERAL EDEMA; POSTHERPETIC NEURALGIA; PRIMARY MEDICAL CARE; PRURITUS; RADICULAR PAIN; RADICULOPATHY; RASH; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SOMNOLENCE; SPINAL CORD DISEASE; STEVENS JOHNSON SYNDROME; SWEATING; THROMBOCYTOPENIA; TRIGEMINUS NEURALGIA; URINARY HESITANCY; URINE RETENTION; VISCERAL PAIN; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 9744273176     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.12.1533     Document Type: Review

References (97)

1. Merskey H, Bogduk N, eds. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle, Wash: IASP Press; 1994.
2. Backonja MM. Defining neuropathic pain [published correction appears in Anesth Analg. 2004;98:67]. Anesth Analg. 2003;97:785-790.
3. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.
4. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441-451.
5. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959-1964.
6. Schwartzman RJ, Grothusen J, Kiefer TR, Rohr P. Neuropathic central pain: epidemiology, etiology, and treatment options. Arch Neurol. 2001;58: 1547-1550.
7. Woolf CJ. Pain. Neurobiol Dis. 2000;7:504-510.
8. Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 1992;355:75-78.
9. Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology. 2002;96:1053-1061.
10. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003;97:1730-1739.
11. Urban MO, Gebhart GF. Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci U S A. 1999;96:7687-7692.
12. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993;52:259-285.
13. Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: basic science mechanisms and clinical effectiveness. J Pain. 2003;4:109-121.
14. Carroll D, Moore RA, McQuay HJ, Fairman F, Tramer M, Leijon G. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev. 2001;3:CD003222.
15. Ji RR, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis. 2001;8:1-10.
16. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5:209-227.
17. McLachlan EM, Janig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature. 1993;363:543-546.
18. Sivilotti L, Woolf CJ. The contribution of GABAA and glycine receptors to central sensitization: disinhibition and touch-evoked allodynia in the spinal cord. J Neurophysiol. 1994;72:169-179.
19. Bennett GJ. Neuropathic pain: an overview. In: Borsook, D, ed. Molecular Neurobiology of Pain. Seattle, Wash: IASP Press; 1997:109-113.
20. Ziegler D, Gries FA, Spuler M, Lessmann F, Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. The epidemiology of diabetic neuropathy. J Diabetes Complications. 1992;6:49-57.
21. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18: 350-354.
22. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
23. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36:877-882.
24. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42.
25. United States Department of Health and Human Services, Centers for Disease Control and Prevention. National Hospital Discharge Survey: Annual Summary, 1990. Hyattsville, Md: National Center for Health Statistics; 1992. Publication PHS 92-1773.
26. Boas R. Complex regional pain syndromes: symptoms, signs, and differential diagnosis. In: Jänig W, Stanton-Hicks M, eds. Reflex Sympathetic Dystrophy: A Reappraisal. Seattle, Wash: IASP Press; 1996:79-92. Progress in Pain Research and Management; vol 6.
27. Boas R. Complex regional pain syndromes: symptoms, signs, and differential diagnosis. In: Jänig W, Stanton-Hicks M, eds. Reflex Sympathetic Dystrophy: A Reappraisal. Seattle, Wash: IASP Press; 1996:79-92. Progress in Pain Research and Management; vol 6.
28. Zakrzewska JM. Trigeminal neuralgia. Clin Evid. 2002;7:1221-1231.
29. Manfredi PL, Foley KM, Payne R, Houde R, Inturrisi CE. Parenteral methadone: an essential medication for the treatment of pain [letter]. J Pain Symptom Manage. 2003;26:687-688.
30. Brew BJ. The peripheral nerve complications of human immunodeficiency virus (HIV) infection. Muscle Nerve. 2003;28:542-552.
31. Kieburtz K, Simpson D, Yiannoutsos C, et al, AIDS Clinical Trial Group 242 Protocol Team. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 1998;51:1682-1688.
32. Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci. 2001;26:21-29.
33. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-1256.
34. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 1990;42:135-144.
35. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc. 2001; 76:511-527.
36. Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfield CA. Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain. 1997;13:324-329.
37. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia. 1993;48:281-285.
38. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology. 2000;55:915-920.
39. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology. 2001;57:1583-1588.
40. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60:1284-1289.
41. Wernicke J, Lu Y, D'Souza D, Waninger A, Tran P. Duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP) [abstract]. J Pain. 2004;5(suppl 1):48. Abstract 756.
42. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002;59(5, suppl 2):S14-S17.
43. Sarantopoulos C, McCallum B, Kwok WM, Hogan Q. Gabapentin decreases membrane calcium currents in injured as well as in control mammalian primary afferent neurons. Reg Anesth Pain Med. 2002;27:47-57.
44. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-1842.
45. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-1836.
46. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931-1937.
47. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25:81-104.
48. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274-1283.
49. Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol. 1986;20:171-184.
50. McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain: a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg. 1999;89:985-988.
51. Nicol CF. A four year double-blind study of tegretol in facial pain. Headache. 1969;9:54-57.
52. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia. 1969;5:215-218.
53. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP. 1990;24: 1214-1219.
54. McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF. Oxcarbazepine: mechanisms of action. Epilepsia. 1994;35(suppl 3):S5-S9.
55. Patsalos PN, Stephenson TJ, Krishna S, Elyas AA, Lascelles PT, Wiles CM. Side-effects induced by carbamazepine-10,11-epoxide [letter]. Lancet. 1985;2:1432.
56. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003;25(5, suppl):S31-S35.
57. Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain. 2004;20:174-178.
58. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184-190.
59. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther. 2002;302: 1168-1175.
60. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59:1015-1021.
61. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71-78.
62. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003;17:576-587.
63. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223-1232.
64. Ebert B, Thorkildsen C, Andersen S, Christrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem Pharmacol. 1998;56:553-559.
65. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000;50:427-440.
66. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-1846.
67. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain. 1999;83:85-90.
68. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213-217.
69. Mao J, Mayer DJ. Spinal cord neuroplasticity following repeated opioid exposure and its relation to pathological pain. Ann N Y Acad Sci. 2001;933: 175-184.
70. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11:203-217.
71. Cohen MJ, Jasser S, Herron PD, Margolis CG. Ethical perspectives: opioid treatment of chronic pain in the context of addiction. Clin J Pain. 2002; 18(4, suppl):S99-S107.
72. Fishman SM, Mahajan G, Jung SW, Wilsey BL. The trilateral opioid contract: bridging the pain clinic and the primary care physician through the opioid contract. J Pain Symptom Manage. 2002;24:335-344.
73. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953.
74. Federation of State Medical Boards of the United States. Model Guidelines for the Use of Controlled Substances for the Treatment of Pain. Dallas, Tex: Federation of State Medical Boards of the United States; 1998.
75. Kalso E, Allan L, Dellemijn PLI, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7:381-386.
76. Steardo L, Leo A, Marano E. Efficacy of baclofen in trigeminal neuralgia and some other painful conditions: a clinical trial. Eur Neurol. 1984;23:51-55.
77. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320:1517-1521.
78. van Hilten BJ, van de Beek WJ, Hoff JI, Voormolen JH, Delhaas EM. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med. 2000;343:625-630.
79. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D, Epidural Clonidine Study Group. Epidural clonidine analgesia for intractable cancer pain. Pain. 1995;61:391-399.
80. Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage. 2003;26:668-677.
81. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997;48:1212-1218.
82. Eide PK, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of postherpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain. 1994;58:347-354.
83. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 1991;41:1024-1028.
84. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain. 2002;18:297-301.
85. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80:533-538.
86. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816-824.
87. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology. 1999;53:1641-1647.
88. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16(2, suppl):S101-S105.
89. Stanton-Hicks M, Baron R, Boas R, et al. Complex Regional Pain Syndromes: guidelines for therapy. Clin J Pain. 1998;14:155-166.
90. Hogan QH, Abram SE. Neural blockade for diagnosis and prognosis: a review. Anesthesiology. 1997;86:216-241.
91. Bernstein RM. Injections and surgical therapy in chronic pain. Clin J Pain. 2001;17(4, suppl):S94-S104.
92. Cicala RS, Thoni K, Angel JJ. Long-term results of cervical epidural steroid injections. Clin J Pain. 1989;5:143-145.
93. Rowlingson JC, Kirschenbaum LP. Epidural analgesic techniques in the management of cervical pain. Anesth Analg. 1986;65:938-942.
94. Rosen CD, Kahanovitz N, Bernstein R, Viola K. A retrospective analysis of the efficacy of epidural steroid injections. Clin Orthop. 1988;228:270-272.
95. North RB, Kidd DH, Zahurak M, James CS, Long DM. Spinal cord stimulation for chronic, intractable pain: experience over two decades. Neurosurgery. 1993;32:384-394.
96. Rainov NG, Heidecke V, Burkert W. Long-term intrathecal infusion of drug combinations for chronic back and leg pain. J Pain Symptom Manage. 2001;22:862-871.
97. Kumar K, Malik S, Demeria D. Treatment of chronic pain with spinal cord stimulation versus alternative therapies: cost-effectiveness analysis. Neurosurgery. 2002;51:106-115.